The World Health Organization on Wednesday said that clinical trials of the anti-malaria drug hydroxychloroquine will resume, having been suspended pending a safety review in the search for coronavirus treatments.
“On the basis of the available mortality data… the executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm,” WHO Chief Tedros Adhanom Ghebreyesus told a virtual news briefing.